Basildon (UK) / Basle (Switzerland), 19 March 2020 – Atnahs (“Atnahs”), a Triton Fund V portfolio company, has acquired the global commercial rights excluding China and Japan for Rocaltrol® (Calcitriol) from F. Hoffmann-La Roche Limited (“Roche”). Rocaltrol® (Calcitriol) is used as an active form of Vitamin D, primarily in the treatment of patients with post-menopausal osteoporosis and renal osteodystrophy.
Atnahs has significantly increased its product portfolio since inception in 2013 through its strong relationships with leading pharma companies. The acquisition is a further step in its ability to deliver medicines that patients, prescribers, healthcare systems and regulators trust and value, as well as building out its Women’s Health franchise.
“This acquisition strengthens our position in Women’s Health, one of our key therapeutic areas. Rocaltrol® has been in the market since 1978 and is a highly recognized brand among patients and prescribers. It is an important step in growing our portfolio of high-quality brands and gives us a deeper presence in Latin America, the Middle East and South East Asia”, says Dr. Amit Patel, CEO of Atnahs.
This transaction also underlines the company’s strong track record of being a preferred acquirer for large cap or specialty pharma companies choosing to divest their established brands. Atnahs just recently announced the acquisition of commercial rights to a portfolio of Cardiovascular medicines used primarily to treat hypertension from AstraZeneca.
Atnahs is a specialty pharmaceutical business, focused on acquiring mature branded medicines out of large cap and specialty pharma companies globally and developing its own niche medicines. Atnahs operates a portfolio of 21 brands with over 1,900 SKUs across more than 144 markets, with a focus on therapeutic areas such as Cardiovascular, Women’s Health & Endocrinology, Neurology & Pain, and Gastroenterology & Oncology.
For further information: www.atnahs.com
Since its establishment in 1997, Triton has sponsored nine funds, focusing on businesses in the industrial, business services, consumer and healthcare sectors. The Triton funds invest in and support the positive development of medium-sized businesses headquartered in Europe.
Triton seeks to contribute to the building of better businesses for the longer term. Triton and its executives wish to be agents of positive change towards sustainable operational improvements and growth.
The 41 companies currently in Triton’s portfolio have combined sales of around €16.5 billion and around 80,000 employees. For further information: www.triton-partners.com
For further information: www.triton-partners.com
For further information: pharmanovia.com
Pharmanovia Press Contact
Kate Antonopoulos, Corporate Marketing & Communications Manager
Phone: +44 1268 943857